Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 21 clinical trials
featured
A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy (SAPPHIRE)

This is an open-label, randomized (1:1), multicenter, Phase 3 clinical trial evaluating the safety and efficacy of nivolumab in combination with investigational agent sitravatinib compared to docetaxel in patients with advanced non-squamous NSCLC who have previously experienced radiographic disease progression on or after treatment with platinum-based chemotherapy in combination with …

cancer chemotherapy
advanced lung cancer
cancer
platinum-based chemotherapy
experimental drug
  • 199 views
  • 05 Mar, 2021
  • 142 locations
featured
A Phase 1/1b Study of Sitravatinib in Combination with Nivolumab and Ipilimumab in Patients with Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid Malignancies

related RTKs including the TAM family (Tyro3/Axl/MERTK), VEGFR2, KIT, and MET. NIVO/IPI are monoclonal antibodies (mAbs) that inhibit the immune checkpoint proteins programmed death receptor-1 (PD-1

monoclonal antibodies
nivolumab
systemic therapy
ipilimumab
carcinoma
  • 27 views
  • 15 Sep, 2020
  • 1 location
Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Non-Small Cell Lung Cancer

The purpose of this study is to evaluate the safety and time to progression of HLA-A*0201 restricted epitope peptides URLC10, VEGFR1 and VEGFR2 emulsified with Montanide ISA 51.

VEGFR2
platelet count
  • 32 views
  • 07 Nov, 2020
  • 1 location
Combination of Chemoradiation Therapy and Epitope Peptide Vaccine Therapy in Treating Patients With Esophageal Cancer

The purpose of this study is to evaluate the safety and immune response of multiple peptides (URLC10, TTK, KOC1 VEGFR1, and VEGFR2) emulsified with Montanide ISA51 in combination with

chemoradiotherapy
ct scan
measurable disease
vaccine therapy
cancer
  • 11 views
  • 07 Nov, 2020
  • 1 location
Camrelizumab Apatinib and Nab-paclitaxel as Second-line Treatment in Advanced Gastric Cancer

This is a Phase I/II , Open-label , Investigator-initiated Trail of Camrelizumab (an Anti-PD-1 Inhibitor), Apatinib (VEGFR2 Inhibitor) and Nab-paclitaxel as Second-line Treatment in Advanced

  • 3 views
  • 23 Jan, 2021
  • 1 location
Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab in Metastatic Carcinoma of the Cervix

The study will integrate the efficacy of combining the anti programmed death-ligand 1 (anti-PD-L1) agent atezolizumab with the current standard of care in Stage IVB , persistent or recurrent carcinoma of the cervix, namely cisplatin or carboplatin/paclitaxel/bevacizumab. It will be explored the combination of bevacizumab plus atezolizumab, with no patient …

  • 62 views
  • 26 Jan, 2021
  • 90 locations
BIOmarker Driven Trial of VEGFR2 Inhibitor in Advanced Sarcoma

The aim of this study is to evaluate the efficacy and safety of Apatinib monotherapy for relapsed or refractory advanced bone and soft tissue sarcoma with VEGFR-2 (KDR) 604A>G polymorphism as predictive biomarker

advanced sarcoma
soft tissue sarcoma
cancer chemotherapy
cancer
VEGFR2
  • 0 views
  • 28 Jan, 2021
  • 1 location
A Study of Anti-VEGFR2 AK109 in Subjects With Advanced Solid Tumors

This is a first in human(FIH) study to characterize the safety, tolerability, pharmacokinetics (PK), immunogenicity and anti-tumor activity of AK109, an anti-VEGFR2 monoclonal antibody, as a

  • 0 views
  • 26 Jan, 2021
  • 1 location
A Phase 1 Study of CX1003 (Kanitinib) in Patients With Advanced Solid Tumors

CX1003 is a novel multi-target tyrosine kinase inhibitor that is designed to primarily inhibit vascular endothelial growth factor receptor 2 (VEGFR2) and hepatocyte growth factor receptor (HGFR

kinase inhibitor
measurable disease
growth factor
VEGFR2
solid tumour
  • 0 views
  • 27 Jan, 2021
  • 1 location
Combination Neoadjuvant Chemotherapy With or Without Apatinib for HER2 Negative Breast Cancer

-negative breast cancer patients. Apatinib is a highly potent human vascular endothelial growth factor receptor 2 (VEGFR2) tyrosine kinase inhibitor that has been independently developed in China, and it

her2/neu-negative breast cancer
paclitaxel
growth factor
VEGFR2
adjuvant therapy
  • 6 views
  • 30 Mar, 2021
  • 1 location